KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Assets Average (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Assets Average for 14 consecutive years, with $96.2 million as the latest value for Q4 2025.

  • Quarterly Assets Average fell 29.33% to $96.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $96.2 million through Dec 2025, down 29.33% year-over-year, with the annual reading at $113.2 million for FY2025, 18.03% down from the prior year.
  • Assets Average hit $96.2 million in Q4 2025 for Arbutus Biopharma, down from $100.5 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $226.4 million in Q2 2022 to a low of $96.2 million in Q4 2025.
  • Historically, Assets Average has averaged $159.6 million across 5 years, with a median of $151.0 million in 2021.
  • Biggest five-year swings in Assets Average: surged 60.76% in 2022 and later tumbled 33.12% in 2025.
  • Year by year, Assets Average stood at $185.0 million in 2021, then increased by 7.87% to $199.6 million in 2022, then dropped by 24.09% to $151.5 million in 2023, then fell by 10.19% to $136.1 million in 2024, then fell by 29.33% to $96.2 million in 2025.
  • Business Quant data shows Assets Average for ABUS at $96.2 million in Q4 2025, $100.5 million in Q3 2025, and $110.1 million in Q2 2025.